|Day's Range||1.3700 - 1.5900|
The mean of analysts' price targets for Pacific Biosciences (PACB) points to a 30.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pacific Biosciences of California fair value estimate is...
PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.